An Optimized Battery of Eight Antibodies That Can Distinguish Most Cases of Epithelial Mesothelioma From Adenocarcinoma
Authors:
Open Access
- 1 August 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 114 (2) , 203-209
Abstract
An immunocytochemical battery comprising 9 antibodies specifically distinguishes 80% of the epithelial malignant mesotheliomas from adenocarcinomas.Keywords
This publication has 15 references indexed in Scilit:
- N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomasCancer, 1999
- Pleural mesothelioma in Sweden: an analysis of the incidence according to the use of asbestos.Occupational and Environmental Medicine, 1999
- Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell typeDiagnostic Cytopathology, 1999
- The European mesothelioma epidemicBritish Journal of Cancer, 1999
- Calretinin: A Novel Immunocytochemical Marker for MesotheliomaAmerican Journal of Surgical Pathology, 1996
- Continuing increase in mesothelioma mortality in BritainThe Lancet, 1995
- Carcinoembryonic antigen‐like reactivity in malignant mesothelioma. A comparison between different commercially available antibodiesCancer, 1994
- Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinomaHuman Pathology, 1993
- Diffuse Epithelial Mesothelioma: A Review of the Ultrastructural SpectrumUltrastructural Pathology, 1987
- Malignant mesotheliomaAmerican Journal of Surgical Pathology, 1982